Roivant Sciences Ltd

Price is extended and overbought following a Bullish Exhaustion signal at new highs, so entries should be deferred until a pullback into rising EMAs or structural support. The medium- and long-term trends remain bullish under Stage 2 advancing dynamics, reinforced by higher highs and lows, rising moving averages, and supportive volume. Mean-reversion entries are not permitted, requiring patience for a cleaner entry.

• ↑Brepacitinib trial shows 73% ACR20 response, driving FDA submission
• ↑Cash position of $4.3 B supports R&D and reduces financing risk
• ↓GAAP EPS −$0.58 misses estimate (−$0.35), prolonging losses